Two peptides dominate tissue-repair research in 2026 — GHK-Cu and BPC-157. They share outcomes but operate through completely different mechanisms. Here’s a vendor-agnostic comparative research review.
KPV — a three-amino-acid fragment of alpha-MSH — has moved from niche immunological tool to one of 2026’s most-discussed short peptides. Here’s what the current research actually shows about mechanism, applications, and sourcing.
The Q1 2026 shutdown of Peptide Sciences, the market’s largest supplier, reshaped research peptide sourcing overnight. Here’s an honest, vendor-agnostic guide to the quality standards that actually matter when choosing a supplier in 2026.
MK-677 is one of the few growth-hormone-class research compounds that is genuinely orally active. Here’s what the 2026 literature shows about its ghrelin receptor activity, research applications, and why capsule format is the standard.
If you’ve seen BPC-157 listed as ‘pentadecapeptide’ on a research catalog and wondered whether they’re the same molecule — they are. Here’s the plain-language breakdown of the scientific name, the sequence, and why the nomenclature matters for research.
BPC-157 is unique among research peptides: it originates in the gastric mucosa, which means oral delivery works differently than with almost any other peptide. Here’s what the 2026 bioavailability research shows about capsules vs. injection for research applications.
